অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - ceftazidime pentahydrate, quantity: 1.164 g (equivalent: ceftazidime, qty 1 g) - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime juno is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antibiotics cannot be used. indications include: severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, e.g., infected burns. respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. severe ear, nose and throat infections: for example: otitis media, mastoiditis. urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

sandoz gmbh - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - ceftriaxone 250 mg - before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, usp and other antibacterial drugs, ceftriaxone for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection, usp is indicated for the treatment of the following infections when caused by susceptible organisms: caused by streptococcus pneumoniae , staphylococcus aureus, ha

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

cardinal health - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - ceftriaxone 1 g - before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, usp and other antibacterial drugs, ceftriaxone for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection, usp is indicated for the treatment of the following infections when caused by susceptible organisms: caused by streptococcus pneumoniae , staphylococcus aureus, ha

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ceftazidime pentahydrate -

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ceftazidime pentahydrate -

মাল্টা - ইংরেজি - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - ceftriaxone - powder for solution for injection/infusion - ceftriaxone 1000 mg - antibacterials for systemic use

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

viatris limited - ceftriaxone sodium 1.079 g equivalent to 1 g ceftriaxone (anhydrous) - powder for injection - 1 g - active: ceftriaxone sodium 1.079 g equivalent to 1 g ceftriaxone (anhydrous) - infections caused by pathogens sensitive to ceftriaxone e.g.: - sepsis; - meningitis; - abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts); - infections of the bones, joints, soft tissue, skin and of wounds; - infections in patients with impaired defence mechanisms; - renal and urinary tract infections; - respiratory tract infections, particularly pneumonia, and ear, nose and throat infections; - genital infections, including gonorrhoea. - perioperative prophylaxis of infections.

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

b. braun medical inc. - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - ceftriaxone 1 g in 50 ml - ceftriaxone for injection and dextrose injection is indicated for the treatment of the following infections when caused by susceptible bacteria. lower respiratory tract infections caused by streptococcus pneumoniae, staphylococcus aureus, haemophilus influenzae, haemophilus parainfluenzae, klebsiella pneumoniae, escherichia coli, enterobacter aerogenes, proteus mirabilis or serratia marcescens . skin and skin structure infections caused by staphylococcus aureus, staphylococcus epidermidis, streptococcus pyogenes, viridans group streptococci, escherichia coli, enterobacter cloacae, klebsiella oxytoca, klebsiella pneumoniae, proteus mirabilis, morganella morganii 1, pseudomonas aeruginosa, serratia marcescens, acinetobacter calcoaceticus, bacteroides fragilis 1 or peptostreptococcus species. complicated and uncomplicated urinary tract infections caused by escherichia coli, proteus mirabilis, proteus vulgaris, morganella morganii or klebsiella pneumoniae . pelvic inflammatory disease caused by neisseria gono

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ceftazidime pentahydrate, quantity: 1164.8 mg (equivalent: ceftazidime, qty 1000 mg) - injection, powder for - excipient ingredients: sodium carbonate - treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime; as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antipseudomonal antibiotics cannot be used. indications include the folowing: severe infections in general (e.g. septicaemia including neonatal sepsis, bacteraemia; in patients in intensive care units with specific problems, e.g. infected burns). respiratory tract (e.g. pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis). severe ear, nose and throat infections (e.g. otitis media, mastoiditis). urinary tract (e.g. acute and chronic pyelonephritis, pyelitis, cystitis - bacterial only; infections associated with bladder and renal stones). skin and soft tissue (e.g. erysipelas abscesses, cellulitis, infected burns and wounds, mastitis). gastrointestinal and abdominal (e.g. intra-abdominal abscesses, enterocolitis). bone and joint (e.g. osteitis, osteomyelitis, septic arthritis, infected burstis).

ইস্রায়েল - ইংরেজি - Ministry of Health

neopharm (israel) 1996 ltd - ceftriaxone as sodium - powder for solution for inj/inf - ceftriaxone as sodium 1000 mg/vial - ceftriaxone - ceftriaxone - * ceftriaxone-fresenius is indicated for the treatment of the following infections in adults and children including term neonates (from birth) :- bacterial meningitis- community acquired pneumonia- hospital acquired pneumonia- acute otitis media- intra-abdominal infections- complicated urinary tract infections (including pyelonephritis)- infections of bones and joints- complicated skin and soft tissue infections- gonorrhoea- syphilis- bacterial endocarditis* ceftriaxone-fresenius may be used:- for treatment of acute exacerbations of chronic obstructive pulmonary disease in adults- for treatment of disseminated lyme borreliosis (early (stage ii) and late (stage iii)) in adults and children including neonates from 15 days of age.- for pre-operative prophylaxis of surgical site infectionsin the management of neutropenic patients with fever that is suspected to be due to a bacterial infectionin the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above* ceftriaxone-fresenius should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum.* consideration should be given to official guidelines on the appropriate use of antibacterial agents.